PCAC: The FDA Committee Deciding Whether BPC-157 Stays Legal to Compound

A beige conference room at the FDA’s White Oak campus in Maryland. A table, a docket number, and two days blocked out on the calendar: July 23 and 24, 2026. That’s where a peptide sold in gyms and biohacker forums across the country went in front of a federal committee that most of the people using it have never heard of.

The committee is called the Pharmacy Compounding Advisory Committee, or PCAC. Spend any time in peptide forums and you’ll eventually see someone confuse it with a different, similarly-named FDA body that reviews drugs for pain and the nervous system. The confusion is understandable. It’s also backwards.

The FDA has at least two advisory committees with near-identical reputations and non-overlapping jobs. Somewhere in Rockville, someone finds that mildly infuriating.

What does PCAC actually do?

PCAC reviews bulk drug substances for Section 503A of the Food, Drug, and Cosmetic Act, the law that lets a compounding pharmacy mix a dose from raw ingredient rather than buy a finished, approved drug. That’s the whole job. Not pain. Not the central nervous system. Compounding eligibility.

The committee people actually mean when they say pain-and-CNS review has its own recent, separate history. The FDA terminated the Peripheral and Central Nervous System Drugs Advisory Committee on June 4, 2026, when its charter expired. The Commissioner reestablished it not long after. None of that touched PCAC. Two committees, two lifespans, one shared habit of getting mixed up in the same forum thread.

PCAC isn’t going anywhere either way. The FDA has already renewed its charter for another two years, so whatever the July docket started, this committee will be around to see it through.

Which peptides actually land in front of PCAC

Getting a hearing doesn’t happen on request. A substance has to be nominated, a public docket has to open for comment, and a meeting has to actually get scheduled and held.

The FDA announced a PCAC meeting for July 23 and 24, 2026, to evaluate bulk drug substances nominated for the Section 503A list and opened a public docket for comment. BPC-157 was on that list. So was the rest of a working slate: KPV, TB-500, and MOTs-C went first, on July 23. Emideltide (better known by its older name, DSIP), Semax, and Epitalon followed the next day.

That wasn’t the whole docket, and it isn’t the whole story either. The same April 2026 FDA action that scheduled July also scheduled a second meeting, before the end of February 2027, for a different slate: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II. What a hearing date actually buys any of these substances, once the room clears and the vote is counted, is a separate question. It’s the one that gets skipped in every forum thread that treats a PCAC date like a launch date.

What does PCAC evaluate, and what falls outside its scope?

PCAC isn’t grading a compound’s clinical promise. Its statutory question is narrower: can this substance be compounded without significant safety concerns, and does it have a legitimate clinical use that justifies a spot on the approved list. That’s not the same question as does this work.

A peptide built around a pain or nervous-system mechanism doesn’t answer only to PCAC. A sponsor chasing full FDA drug approval, rather than compounding eligibility, runs into a different committee entirely: the pain committee for pain claims, the nervous-system committee for CNS claims. The FDA is renewing the pain committee too, on its own separate track. What isn’t established is how often that overlap actually plays out for a peptide in practice. No PCAC peptide review has been documented sitting alongside a parallel pain or nervous-system review of the same compound. It might happen. It hasn’t been shown to happen yet.

PCAC’s own track record with peptides before July 2026 isn’t in any public file we could find. No prior peptide votes. No prior denials. No comparison case to hold this one against. July 2026 is the committee’s first real run at peptides as a category, not its fiftieth.

What the July 2026 vote actually decided

BPC-157 came out of the July 23 session with a recommendation for inclusion on the 503A Bulk Drug Substances list. TB-500 got its own separate recommendation the same day, also for inclusion. Both votes were close. Legal-trade coverage of the meeting puts BPC-157’s tally at roughly 8 to 6 with one abstention, and describes a similar 8-to-6, one-abstention split on TB-500’s separate ballot. The FDA’s own vote sheet hasn’t posted yet.

None of that is final. PCAC recommends. The FDA decides, through its own rulemaking process, on its own timeline, and that decision hasn’t been made. The agency’s public position today is the same one it held the day before the meeting: BPC-157 has no FDA-approved NDA or BLA, and no FDA-approved form of BPC-157 exists for human use.

Trade coverage of the same two days describes most of the July slate faring similarly. FDA’s own per-substance tally sheet for KPV, MOTs-C, Emideltide, Semax, and Epitalon hasn’t been published as of this writing. Treat that as reported, not confirmed.

Does a PCAC recommendation mean a peptide is approved?

A recommendation for the 503A list is not a green light, and it isn’t close to one. Inclusion on that list, if the FDA acts on it, means a compounding pharmacy is legally allowed to mix a dose from bulk BPC-157. It says nothing about whether the dose does what the person taking it hopes it does. Two different questions. Two different processes. PCAC only touches one of them.

Whether 503A eligibility tracks with a peptide’s clinical evidence, in either direction, isn’t established by PCAC’s own review criteria. The committee’s questions are about safety and compounding legitimacy, not about ranking evidence quality against a felt sense of what should work. A peptide can clear PCAC on a thin human data set. A peptide with a thicker data set could, in principle, not clear it. Neither outcome would be a surprise, because that isn’t what the vote measures.

Two lists, moving in opposite directions

None of the substances on the July docket, BPC-157 included, were ever on the FDA’s Category 1 list, the enforcement-discretion bucket that lets a pharmacy compound something while it’s under review. According to FDA’s own compounding-substance history, BPC-157 moved into Category 2, the do-not-compound list, in September 2023, coming from unclassified status rather than down from Category 1. It came off that list around April 2026, per the same record. Off the banned list isn’t the same as on an approved one. It sits in the gap between the two: no longer flagged as unsafe, not yet authorized. The July vote is the mechanism for closing that gap, if the FDA follows through.

The same crackdown machinery is already reshaping compounds that haven’t had their PCAC hearing yet. GHK-Cu is the clearest case. Push it through a needle into the bloodstream, and that injectable form recently came off Category 2, the same do-not-compound bucket BPC-157 just left. Rub the same peptide into skin as a cream, and the topical form got pulled out of Category 1, the list that had let pharmacies compound it under enforcement discretion. One peptide, two physical forms, moving in opposite directions, both scheduled for the February 2027 docket.

What it would take to reach prescription status

Getting from a PCAC recommendation to a bottle with a prescription label on it is a longer road than most forum threads imply. PCAC only touches compounding eligibility under Section 503A. Full drug approval, the kind that puts a peptide on a pharmacy shelf as a standard prescription, runs through an entirely separate FDA process, one that takes years of clinical trials and its own complete review. Section 503A eligibility and full drug approval aren’t the same finish line. They aren’t even the same race.

No one can say today whether that longer road exists for BPC-157, or for any peptide on either the July or February docket. The public record doesn’t answer that question, because the question hasn’t been tested yet.

PCAC decided something about BPC-157 in July 2026. It did not decide whether BPC-157 works, whether it’s safe over the long run, or whether it will ever carry an FDA-approved label. Those are three separate, still-open questions. And the FDA’s own answer on the fourth one, what actually happens to the 503A list, hasn’t come yet. If you’re watching this space because you want to know when BPC-157 goes legit, that answer is still being written.